Novartis’s Detailed Pelacarsen Data Leave Little Hope For Other Lp(a)-Lowering Drugs

In Lp(a)HORIZON, lipoprotein(a) levels fell by 78.4% in pelacarsen-treated patients, but with a few more cardiovascular events than in the Phase III trial’s placebo group. A NEJM publication said other Lp(a)-reducing candidates may still deliver positive data, but analysts were skeptical.